{
    "clinical_study": {
        "@rank": "158248", 
        "arm_group": [
            {
                "arm_group_label": "A-prexa", 
                "arm_group_type": "Experimental", 
                "description": "A-prexa 5, 10mg"
            }, 
            {
                "arm_group_label": "Zyprexa", 
                "arm_group_type": "Active Comparator", 
                "description": "Zyprexa 5, 10mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of A-prexa compared to\n      Zyprexa in patients with schizophrenia, schizophreniform disorder and schizoaffective\n      disorder."
        }, 
        "brief_title": "Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Schizophrenia", 
            "Schizophreniform Disorder", 
            "Schizoaffective Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Psychotic Disorders", 
                "Schizophrenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20 years to 65 years\n\n          -  Schizophrenia patient with an acute exacerbation\n\n          -  Understand the requirement of the study and voluntarily consent to participate in the\n             study\n\n        Exclusion Criteria:\n\n          -  Patients who have another psychiatric disorders\n\n          -  Patients who have unstable medical conditions\n\n          -  Patients who have clinically important abnormalities of liver function test (\uff1e2.5\n             fold of upper normal limit), ECG and vital sign at screening visit\n\n          -  Uncontrolled diabetic patients (plasma glucose level is more than 126 mg/dl in\n             fasting condition)\n\n          -  Patients who have a history of an allergic reaction to olanzapine\n\n          -  Patient who have no clinical response to take two or more different atypical\n             anti-psychotics for more than 4 weeks.\n\n          -  Patient who take clozapine within 12 weeks before screening visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137993", 
            "org_study_id": "CJ_OLZ_401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Zyprexa", 
                "description": "A-prexa 5-20 mg for 6 weeks", 
                "intervention_name": "A-prexa", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A-prexa", 
                "description": "Zyprexa 5-20 mg for 6 weeks", 
                "intervention_name": "Zyprexa", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Olanzapine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 11, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Randomized, Double Blind, Parallel, Phase\u2163 Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline at 6 week in total PANSS score", 
            "safety_issue": "No", 
            "time_frame": "6 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline at 1, 2, 4 and 6 week in total PANSS score.", 
                "safety_issue": "No", 
                "time_frame": "6 week"
            }, 
            {
                "measure": "Responder to be decreased of 30% or more in PANSS total score from baseline at 6 week", 
                "safety_issue": "No", 
                "time_frame": "6 week"
            }, 
            {
                "measure": "Change from baseline at 6 week in total CGI-S score", 
                "safety_issue": "No", 
                "time_frame": "6 week"
            }, 
            {
                "measure": "Responder rate in CGI-I score of 'very much improved', 'much improved' and 'minimally improved'", 
                "safety_issue": "No", 
                "time_frame": "6 week"
            }
        ], 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}